Puma Biotechnology Inc Common Stock (PBYI)

About PBYI

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The c…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

179

Website

www.pumabiotechnology.com/

Fundamentals

1-day range

$9.02$9.24

Market cap

$391.42M

P/E (trailing)

18.65

P/E (forward)

25.89

EPS (trailing)

$0.48

Dividend yield

—

Beta

1.24

Avg. volume

324.2K

Puma Biotechnology Inc Common Stock Competitors

Chosen by industry and closest market cap.

• PBYI

  Puma Biotechnology Inc Common Stock

  $9.07

  ▼ 1.89%
  Market cap $391.42MP/E 18.65
  $4.3$9.51
• EOLS

  Evolus Inc. Common Stock

  $8.89

  ▲ 0.06%
  Market cap $398.42MP/E —
  $3.86$9.12
• ENTA

  Enanta Pharmaceuticals Inc. Common Stock

  $13.6

  ▼ 1.45%
  Market cap $376.57MP/E —
  $7.05$17.15
• RCKT

  Rocket Pharmaceuticals Inc. Common Stock

  $3.86

  ▲ 6.49%
  Market cap $372.35MP/E —
  $2.53$5.45
• LRMR

  Larimar Therapeutics Inc. Common Stock

  $4

  ▼ 1.23%
  Market cap $413.45MP/E —
  $2.72$6.42
• KMDA

  Kamada Ltd. Ordinary Shares

  $8.29

  ▲ 0.36%
  Market cap $417.07MP/E 20.65
  $6.5$9.35
• BNTC

  Benitec Biopharma Inc. Common Stock

  $12.51

  ▼ 1.30%
  Market cap $417.41MP/E —
  $9.85$16.76

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6
  benzinga · 8/7/2026

Institutional Ownership

March 31, 2026

Total shares held

35.74M

Total value held

$207.30M

Institutional holders

152